Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
ChEMBL ligand: CHEMBL6 (Aconip, Artracin, Artracin sr, Berlind 75 ret, Durametacin, Flexin-25 continus, Flexin-50 continus, Flexin-75 continus, Imbrilon, Indocid-r, Indocid ret, Indocin, Indocin sr, Indoderm, Indoflex, Indolar, Indolar sr, Indo-lemmon, Indomax-25, Indomax-75 sr, Indometacin, Indometacin farnesil, Indometacinum, Indomethacin, Indomod, Indo-paed, Indoptol, Indotard mr 75, Ledmecin, Maximet sr, Mobilan, NSC-757061, NSC-77541, Pardelprin mr, Reumacide, Rheumacin la, Rimacid, Slo-indo, Tivorbex) |
---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
---|---|---|---|---|---|---|---|---|
Aldo-keto reductase family 1 member C1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5905] [UniProtKB: Q04828] | ||||||||
ChEMBL | Discontinuous Radiometric Assay: Compounds may be evaluated as selective reversible inhibitors of AKR1C3 by screening them against homogeneous recombinant AKR1C1-AKR1C4 expressed in E. coli. In each case, a discontinuous radiometric assay may be used to monitor the inhibition of progesterone reduction (20-ketosteroid reduction) catalyzed by AKR1C1, the inhibition of Δ4-AD reduction (17-ketosteroid reduction) catalyzed by AKR1C3, and the inhibition of 5α-DHT reduction (3-ketosteroid reduction) catalyzed by AKR1C2 and AKR1C4 (by measuring the formation of 20α-hydroxyprogesterone, testosterone or 3α-androstanediol by radiochromatography). Secondary screens of the compounds of interest include: (a) a full-screen against all nine human recombinant AKR enzymes to ensure there are no-intended off-target effects (in this context AKR1B10 (retinal reductase; SEQ ID NO:5) has been shown to be potently inhibited by N-phenylanthranilates) (Endo et al., 2010, Biol. Pharm. Bull. 33:886-90); (b) a screen against COX-1 and COX-2 to reaffirm that compounds do not act as NSAIDs; and (c) an expanded screen against other nuclear receptors (especially other steroid hormone receptors). | B | 4 | pKi | >100000 | nM | Ki | US-9271961-B2. Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof (2016) |
ChEMBL | Inhibition of human recombinant N-terminal His6-tagged AKR1C1 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis | B | 4 | pIC50 | >100000 | nM | IC50 | J Med Chem (2012) 55: 7746-7758 [PMID:22877157] |
Aldo-keto reductase family 1 member C2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5847] [UniProtKB: P52895] | ||||||||
ChEMBL | Discontinuous Radiometric Assay: Compounds may be evaluated as selective reversible inhibitors of AKR1C3 by screening them against homogeneous recombinant AKR1C1-AKR1C4 expressed in E. coli. In each case, a discontinuous radiometric assay may be used to monitor the inhibition of progesterone reduction (20-ketosteroid reduction) catalyzed by AKR1C1, the inhibition of Δ4-AD reduction (17-ketosteroid reduction) catalyzed by AKR1C3, and the inhibition of 5α-DHT reduction (3-ketosteroid reduction) catalyzed by AKR1C2 and AKR1C4 (by measuring the formation of 20α-hydroxyprogesterone, testosterone or 3α-androstanediol by radiochromatography). Secondary screens of the compounds of interest include: (a) a full-screen against all nine human recombinant AKR enzymes to ensure there are no-intended off-target effects (in this context AKR1B10 (retinal reductase; SEQ ID NO:5) has been shown to be potently inhibited by N-phenylanthranilates) (Endo et al., 2010, Biol. Pharm. Bull. 33:886-90); (b) a screen against COX-1 and COX-2 to reaffirm that compounds do not act as NSAIDs; and (c) an expanded screen against other nuclear receptors (especially other steroid hormone receptors). | B | 4 | pKi | >100000 | nM | Ki | US-9271961-B2. Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof (2016) |
ChEMBL | Inhibition of human recombinant N-terminal His6-tagged AKR1C2 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis | B | 4 | pIC50 | >100000 | nM | IC50 | J Med Chem (2012) 55: 7746-7758 [PMID:22877157] |
ChEMBL | Inhibition of human recombinant AKR1C2 expressed in Escherichia coli using S-tetralol as substrate by fluorometry | B | 4.12 | pIC50 | 75000 | nM | IC50 | J Nat Prod (2012) 75: 716-721 [PMID:22506594] |
ChEMBL | Inhibition of human recombinant AKR1C2-mediated NADP+-dependent oxidation of S-(+)-1,2,3,4-tetrahydro-1-naphthol | B | 4.44 | pIC50 | 36530 | nM | IC50 | J Med Chem (2013) 56: 2429-2446 [PMID:23432095] |
AKR1C3/Aldo-keto-reductase family 1 member C3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4681] [GtoPdb: 1382] [UniProtKB: P42330] | ||||||||
ChEMBL | Discontinuous Radiometric Assay: Compounds may be evaluated as selective reversible inhibitors of AKR1C3 by screening them against homogeneous recombinant AKR1C1-AKR1C4 expressed in E. coli. In each case, a discontinuous radiometric assay may be used to monitor the inhibition of progesterone reduction (20-ketosteroid reduction) catalyzed by AKR1C1, the inhibition of Δ4-AD reduction (17-ketosteroid reduction) catalyzed by AKR1C3, and the inhibition of 5α-DHT reduction (3-ketosteroid reduction) catalyzed by AKR1C2 and AKR1C4 (by measuring the formation of 20α-hydroxyprogesterone, testosterone or 3α-androstanediol by radiochromatography). Secondary screens of the compounds of interest include: (a) a full-screen against all nine human recombinant AKR enzymes to ensure there are no-intended off-target effects (in this context AKR1B10 (retinal reductase; SEQ ID NO:5) has been shown to be potently inhibited by N-phenylanthranilates) (Endo et al., 2010, Biol. Pharm. Bull. 33:886-90); (b) a screen against COX-1 and COX-2 to reaffirm that compounds do not act as NSAIDs; and (c) an expanded screen against other nuclear receptors (especially other steroid hormone receptors). | B | 5.09 | pKi | 8200 | nM | Ki | US-9271961-B2. Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof (2016) |
ChEMBL | Inhibition of AKR1C3 (unknown origin) | B | 5.13 | pIC50 | 7350 | nM | IC50 | J Med Chem (2021) 64: 1786-1815 [PMID:33569941] |
ChEMBL | Inhibition of N-terminal GST-tagged recombinant human AKR1C3 His5Gln mutant expressed in Escherichia coli BL21 (DE) Codon Plus RP cells assessed as reduction in NADPH production | B | 5.13 | pIC50 | 7350 | nM | IC50 | ACS Med Chem Lett (2019) 10: 437-443 [PMID:30996776] |
ChEMBL | Inhibition of N-terminal His-tagged human AKR1C3 (1 to 323 residues) expressed in Escherichia coli using 4-adione as substrate in presence of NADPH by fluorescence method | B | 5.14 | pIC50 | 7260 | nM | IC50 | J Med Chem (2020) 63: 11305-11329 [PMID:32463235] |
ChEMBL | Inhibition of human recombinant AKR1C3 expressed in Escherichia coli JM109 cells using S-tetralol as substrate by fluorometry | B | 5.39 | pIC50 | 4100 | nM | IC50 | J Nat Prod (2012) 75: 716-721 [PMID:22506594] |
ChEMBL | Inhibition of AKR1C3 (unknown origin) using 9,10-phenanthrenequinone as substrate | B | 5.64 | pIC50 | 2300 | nM | IC50 | J Med Chem (2020) 63: 11305-11329 [PMID:32463235] |
ChEMBL | Inhibition of AKR1C3 using 9,10-phenanthroquinone as substrate | B | 5.64 | pIC50 | 2300 | nM | IC50 | J Med Chem (2012) 55: 7746-7758 [PMID:22877157] |
ChEMBL | Inhibition of human recombinant N-terminal His6-tagged AKR1C3 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis | B | 6.14 | pIC50 | 730 | nM | IC50 | J Med Chem (2012) 55: 7746-7758 [PMID:22877157] |
ChEMBL | Inhibition of human recombinant AKR1C3-mediated NADP+-dependent oxidation of S-(+)-1,2,3,4-tetrahydro-1-naphthol | B | 7 | pIC50 | 100 | nM | IC50 | J Med Chem (2013) 56: 2429-2446 [PMID:23432095] |
Aldo-keto reductase family 1 member C4 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4999] [UniProtKB: P17516] | ||||||||
ChEMBL | Inhibition of human recombinant N-terminal His6-tagged AKR1C4 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis | B | 4 | pIC50 | >100000 | nM | IC50 | J Med Chem (2012) 55: 7746-7758 [PMID:22877157] |
ChEMBL | Inhibition of human recombinant GST-tagged AKR1C4 expressed in Escherichia coli using S-tetralol as substrate by fluorometry | B | 4.27 | pIC50 | 54000 | nM | IC50 | J Nat Prod (2012) 75: 716-721 [PMID:22506594] |
aldo-keto reductase family 1 member B/Aldose reductase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1900] [GtoPdb: 2768] [UniProtKB: P15121] | ||||||||
ChEMBL | In vitro inhibition of rabbit lens aldose reductase. | B | 5.22 | pIC50 | 6000 | nM | IC50 | J Med Chem (1986) 29: 2347-2351 [PMID:3097317] |
Aldose reductase in Bovine (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3081] [UniProtKB: P16116] | ||||||||
ChEMBL | Inhibition of Aldose reductase (AR) | B | 5.3 | pIC50 | 5000 | nM | IC50 | J Med Chem (2001) 44: 1718-1728 [PMID:11356107] |
aldo-keto reductase family 1 member B/Aldose reductase in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2622] [GtoPdb: 2768] [UniProtKB: P07943] | ||||||||
ChEMBL | DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde) | B | 5.44 | pIC50 | 3631 | nM | IC50 | DrugMatrix in vitro pharmacology data |
Androgen receptor/Androgen Receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1871] [GtoPdb: 628] [UniProtKB: P10275] | ||||||||
ChEMBL | Agonist activity at androgen receptor (unknown origin) expressed in HeLa cells co-expressing PSA-(ARE)4-Luc13 assessed as induction of DHT-induced luciferase activity after 20 mins by luciferase reporter gene assay | B | 9.85 | pEC50 | 0.14 | nM | EC50 | J Med Chem (2013) 56: 2429-2446 [PMID:23432095] |
5-LOX/Arachidonate 5-lipoxygenase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL215] [GtoPdb: 1385] [UniProtKB: P09917] | ||||||||
ChEMBL | Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay | F | 5.15 | pIC50 | 7000 | nM | IC50 | J Med Chem (1997) 40: 819-824 [PMID:9057869] |
5-LOX/Arachidonate 5-lipoxygenase in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL312] [GtoPdb: 1385] [UniProtKB: P12527] | ||||||||
ChEMBL | Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay | B | 4 | pIC50 | >100000 | nM | IC50 | Bioorg Med Chem Lett (1992) 2: 705-708 |
ChEMBL | Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1) | B | 4 | pIC50 | >100000 | nM | IC50 | Bioorg Med Chem Lett (1992) 2: 1655-1660 |
ChEMBL | Inhibition of 5-lipoxygenase in intact RBL-1 cell line | B | 4 | pIC50 | >100000 | nM | IC50 | J Med Chem (1990) 33: 2070-2072 [PMID:2115586] |
ChEMBL | Inhibitory activity against 5-lipoxygenase of RBL-1 cell line | B | 4.6 | pIC50 | >25000 | nM | IC50 | J Med Chem (1992) 35: 3148-3155 [PMID:1507204] |
ChEMBL | Inhibition of 5-lipoxygenase in rat RBL-1 cells | B | 4.7 | pIC50 | >>20000 | nM | IC50 | J Med Chem (1990) 33: 1163-1170 [PMID:2319562] |
ChEMBL | Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate | F | 4.92 | pIC50 | 12000 | nM | IC50 | J Med Chem (1997) 40: 819-824 [PMID:9057869] |
CB1 receptor/Cannabinoid CB1 receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL218] [GtoPdb: 56] [UniProtKB: P21554] | ||||||||
ChEMBL | Evaluated for binding affinity against recombinant human central cannabinoid receptor 1 | B | 4.7 | pKi | >20000 | nM | Ki | Bioorg Med Chem Lett (1996) 6: 2263-2268 |
CB2 receptor/Cannabinoid CB2 receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL253] [GtoPdb: 57] [UniProtKB: P34972] | ||||||||
ChEMBL | Evaluated for binding affinity against recombinant human peripheral cannabinoid receptor 2 | B | 4.7 | pKi | >20000 | nM | Ki | Bioorg Med Chem Lett (1996) 6: 2263-2268 |
COX-1 /Cyclooxygenase-1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL221] [GtoPdb: 1375] [UniProtKB: P23219] | ||||||||
ChEMBL | Binding affinity to COX1 (unknown origin) | B | 6.6 | pKd | 253 | nM | Kd | Med Chem Res (2012) 21: 3491-3498 |
ChEMBL | Inhibition of COX1 (unknown origin) | B | 4.9 | pIC50 | 12500 | nM | IC50 | Bioorg Med Chem Lett (2015) 25: 2931-2936 [PMID:26048794] |
ChEMBL | Inhibitory concentration against human recombinant Prostaglandin G/H synthase 1 cloned and expressed in baculovirus (Sf9) | B | 4.91 | pIC50 | 12400 | nM | IC50 | Bioorg Med Chem Lett (2001) 11: 1325-1328 [PMID:11392547] |
ChEMBL | Inhibition of COX1 in human platelet microsomes assessed as reduction in formation of oxidized TMPD using arachidonic acid as substrate preincubated for 3 to 5 mins followed by arachidonic acid addition measured for 25 secs by spectrophotometric assay | B | 4.92 | pIC50 |